PCA-062

N/A

Report date: 2024/02/05 14:07:25

Base Information

Drug NamePCA-062

Drug Alias NamePCA-pCADPCA-062

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > SMCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionCadherin 3 inhibitors

TargetsCadherin 3

Therapy Area/IndicationsHead and Neck NeoplasmsEsophageal NeoplasmsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSingaporeItaly +[6]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Pharma Ag

Active IndicationsN/A

Inactive IndicationsHead and Neck NeoplasmsEsophageal NeoplasmsTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A